Background
==========

Nonsyndromic cleft lip with or without cleft palate (NSCLP \[MIM 119530\]) is one of the most common human craniofacial birth defects, with both genetic and environmental components involved in its etiology \[[@B1]\]. Its prevalence rate ranges from 1/300 to 1/2500 depending on the ethnic origin of the populations \[[@B2]\]. NSCLP presents a wide variety of primary and secondary medical complications in its rehabilitation. This fact plus medical costs and the emotional burden to patients and their families makes NSCLP a public health problem \[[@B3]\].

The identification of genetic risk factors in NSCLP has been the subject of intensive research in the last decades. In the past few years, the list of NSCLP candidate genes has rapidly increased and their study has been mainly focused in the search for coding mutations \[[@B4]\]. Some reports have estimated that the contribution of certain genes to NSCLP such as *MSX1*accounts for 2%, *IRF6*12-17% and 6% for the aggregate contribution of *FOXE1*, *GLI2*, *MSX2*, *SKI*, *SATB2*and *SPRY2*\[[@B5]-[@B8]\]. The increased knowledge that has emerged from all these reports has permitted an improvement in the knowledge of genetic factors involved in NSCLP, especially in families showing a familial aggregation of this disorder \[[@B9]-[@B11]\].

An attractive NSCLP candidate gene is bone morphogenetic protein 4 (*BMP4*, 14q22-23 in humans), a member of the transforming growth factor-beta superfamily. BMP signals regulate many aspects of skeletal development, including cartilage and bone formation during craniofacial and limb development \[[@B12]\]. Gong and Guo have reported that the *Bmp4*expression localizes at the site of fusion of the mice facial prominences \[[@B13]\]. The conditional inactivation of *Bmp4*in a transgenic mice line results in an isolated cleft lip \[[@B14]\]. The findings of these studies imply that the function of *Bmp4*in the ectoderm of the facial processes is to regulate lip fusion.

In humans, few studies on the role of *BMP4*in NSCLP have been reported. Lidral and Moreno performed a genome wide scan meta-analysis that showed evidence of linkage between NSCLP and the chromosomal region 14q21-24 \[[@B15]\]. Lin et al. performed an association study in a Chinese population using the non-synonymous single-nucleotide polymorphism (SNP) of *BMP4*, rs17563 (p.Val152Ala) and described that the C allele carriers showed an increased risk for NSCLP \[[@B16]\]. Recently, Jianyan et al. and Lin et al. have reported an interaction between rs17563 and environmental factors like maternal passive smoking in the expression of NSCLP \[[@B17],[@B18]\]. The *BMP4*coding sequence was analyzed by Suzuki et al. in a sample of patients with subepithelial, microform and overt cleft lip \[[@B19]\]. These authors detected missense and nonsense mutations in 0.7% of these patients which were absent in controls. All these findings support a role for genetic variation of *BMP4*in the pathogenesis of NSCLP.

Our group recently reported a mutation screening analysis of *BMP4*in a sample of 150 Chilean NSCLP case-parent trios. This analysis considered the coding regions (exons and exon-intron boundaries) and exclude regulatory regions. Due to the absence of causal mutations, we decided to genotype three SNPs (two intronic and one located 5 kb upstream to *BMP4*) in this same sample of triads. Significant deviations from expected transmissions were observed for haplotypes conformed by rs1957860 and rs762642 \[[@B20]\]. These polymorphisms delimitate a genomic region where a promoter and an enhancer of *BMP4*are located \[[@B21]\]. Consequently, in this new study we searched for NSCLP risk variants within the two *BMP4*promoters: BMP4.1 (located upstream from exon 1) and BMP4.2 (located upstream from exon 2) (Figure [1](#F1){ref-type="fig"}) \[[@B22]\] by direct sequencing in a case-control Chilean sample.

![**Basic structure of human *BMP4*gene and their two promoters**. Exons (boxes) are indicated by numbers 1 to 5. Upper panel shows the position of promoter 1 (BMP4.1) and promoter 2 (BMP4.2) and the location of the SNPs associated with NSCLP in a previous study (Suazo et al., 2010). Lower panel shows a more detailed view of the two promoters segment indicating the position of the novel and/or risk variants detected in the present study.](1471-2350-12-163-1){#F1}

Methods
=======

Patients and controls
---------------------

Our study group consisted of 167 unrelated NSCLP cases and 336 controls. The distribution of cases by gender was 64% males and 36% females. Among cases, 115 were sporadic (9 cleft lip and 106 cleft lip and palate) and 52 had a positive family history (5 cleft lip and 47 cleft lip and palate). The patients were identified and interviewed during the course of clinical examinations between the years 2008 and 2011 in the following centers: Cleft Lip/Palate Clinic, School of Dentistry, University of Chile; Dental Service, Hospital Roberto del Rio; Cleft Lip/Palate Center, Hospital Exequiel Gonzalez Cortes; Maxillofacial Service, Hospital San Borja-Arriaran; Maxillofacial Service, Hospital Sotero del Rio (all of them located in the city of Santiago, Chile) and at the Corporation for the Help of Cleft Children (located in the city of La Serena, which is approximately 400 kilometers north from Santiago, Chile). In-depth interviews of at least three family members were conducted to provide detailed familiar information. A careful anamnesis was carried out to evaluate the use of teratogenic substances, such as phenytoin, warfarin and ethanol during pregnancy. The control group was recruited from blood donors of the Blood Bank, Hospital San Jose. After a careful interview those with a negative family history of orofacial clefts were incorporated in the study. The gender distribution of controls was 55% males and 45% females. The Institutional Review Boards of the Faculty of Medicine of the University of Chile and of the National Fund for Science and Technological Development (FONDECYT) approved our study and all participants gave their informed consent.

The contemporary urban Chilean population is mainly the result of the admixture between Amerindians (of Asian origin) and the Spanish settlers initiated in the XVI and XVII centuries \[[@B23]\]. The relationship between Amerindian admixture, socioeconomic strata, and prevalence of NSCLP has been extensively studied in Chile \[[@B24],[@B25]\]. All individuals included in our study belong to the middle-low and low socioeconomic strata which show the highest rates of Amerindian admixture and NSCLP \[[@B25]\].

Molecular Analysis
------------------

*Genomic DNA purification:*Genomic DNA was extracted from peripheral blood white cells according to the method described by Chomczynsky and Sacchi \[[@B26]\].

*BMP4 promoters sequencing:*the genomic segments corresponding to BMP4.1 and BMP4.2 were amplified by the polymerase chain reaction (PCR). The primers were designed using the on-line tool *Primer3*<http://frodo.wi.mit.edu/primer3/> taking as reference BMP4.1 and BMP4.2 sequences described by Van den Wijngaard et al. and deposited in GeneBank (accession numbers [AF035427.1](AF035427.1) and [AF035428.1](AF035428.1), respectively) \[[@B24]\]. BMP4.1 was described as a 1097 bp segment (chromosome position GRCh37:14:54424710-54423613) and BMP4.2 as a 1212 bp segment (chromosome position GRCh37:14:54422436-54421219) (Figure [1](#F1){ref-type="fig"}). Given that the maximum length for an appropriate sequence lecture of a segment is 850 bp, these promoters were amplified in two overlapping fragments. For this purpose AmpliTaq Gold^®^360 (Applied Biosystems) was used as DNA polymerase applying 35 amplification cycles according to the manufacturer recommendations. Primers, length of amplified fragments and annealing temperature are listed in Additional File [1](#S1){ref-type="supplementary-material"}. All PCR products were visualized by 1.5% agarose gel electrophoresis and sent to Macrogen Inc. (Seoul, Korea) where they were sequenced using the forward primer. Samples with variants not previously described were also sequenced with the reverse primer to confirm these findings.

Bioinformatic Analyses
----------------------

The presence of SNPs previously described within BMP4.1 and BMP4.2 was examined using the *SNP BLAST*tool <http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_SPEC=SNP&BLAST_PROGRAMS=megaBlast&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=dbSNP_homepage>. Sequencing results were analyzed by multiple alignments using the *ClustalW2*program <http://www.ebi.ac.uk/Tools/msa/clustalw2/> comparing them with the aforementioned reference sequences deposited in *GeneBank*. For sequence variants detected in cases but not in controls and for those associated with NSCLP, their capability to disrupt or create mammalian transcription factor binding motifs was predicted. For this purpose the softwares *Tfsitescan*<http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl> and *MatInspector*<http://www.genomatix.de/en/index.html> were used.

Statistical Analyses
--------------------

Allele and genotype frequencies of the BMP4.1 and BMP4.2 polymorphisms were estimated as simple proportions in cases and controls. An exact test to assess Hardy-Weinberg equilibrium implemented in the *Arlequin*statistical package was used in these polymorphisms \[[@B27]\]. To evaluate the association between NSCLP and BMP4.1 and/or BMP4.2 polymorphisms, allele and genotype Odds Ratio (OR) with 95% confidence intervals (C.I.) were estimated for the total sample and subdivided by gender. These analyses were performed using the *UNPHASED*program that applies a global likelihood-ratio significance test that does not require corrections for multiple comparisons \[[@B28]\]. Additionally, *UNPHASED*gives a likelihood-ratio test specific for each allele and genotype \[[@B28]\]. Parallel association analyses were carried out with *PLINK*software \[[@B29]\].

Results
=======

The analysis of both *BMP4*promoters in cases detected the presence of novel genetic variants. Four of them were found in BMP4.1: c.-5514G \> A, c.-5365C \> T, c.-5109A \> C and c.-5049C \> T located at nucleotide 54424454, 54424305, 54424109 and 54423989 respectively (according to genome assembly GRCh37; Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The variants c.-5514G \> A and c.-5109A \> C were present in a heterozygous state in two different cases. The other two variants, c.-5365T and c.-5049T, were found in one male case which inherited them from his healthy mother possibly conforming a haplotype. Among these variants only c.-5109A \> C was detected in one of the 336 controls (OR = 2.09; 95% C.I. = 0.13-33.52; p = 0.543) (data not shown). In BMP4.2 only one novel variant was detected corresponding to an eight base pairs deletion (c.-3066\_-3059delAACCCGGG; Figures [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}) in 3.9% of cases and in 5.9% of controls. No statistical differences between both group were observed (OR = 0.65; 95% C.I. = 0.33-1.27; p = 0.202; Table [1](#T1){ref-type="table"}). Despite its frequency, this variant has not been previously described in genomic databases like *Ensembl*or *Human Mutation Database*.

![**Novel variants detected within BMP4**.1 promoter. A) c.-5514G \> A. Left panel: sequence showing A/G change. Right panel: sequence without change. B) c.-5365C \> T. Left panel: sequence showing T/C change. Right panel: sequence without change. C) c.-5109A \> C. Left panel: sequence showing C/A change. Right panel: sequence without change. D) c.-5049C \> T. Left panel: sequence showing T/C change. Right panel: sequence without change.](1471-2350-12-163-2){#F2}

![**A Novel variant detected within BMP4.2 promoter**. A) Sequence of a genomic region showing deletion AACCCGGG (c.-3066_c.-3059) within BMP4.2 promoter in a heterozygous individual. B) Sequence of the same genomic segment from an individual without deletion.](1471-2350-12-163-3){#F3}

###### 

Polymorphic variants detected within BMP4.1 and BMP4.2 in NSCLP cases and controls

  Promoter   Polymorphism   Genetic position   Chromosome position^a^   Variation    MAF^b^   Odds Ratio (95% C.I.)   p-value             
  ---------- -------------- ------------------ ------------------------ ------------ -------- ----------------------- ------------------- -------
  BMP4.1     rs2855527      c.-5729            54424669                 T \> G       0.0032   0.0030                  1.04 (0.09-11.55)   0.972
             rs77671695     c.-5098            54424038                 T \> G       0.040    0.055                   0.72 (0.37-1.38)    0.322
                                                                                                                                          
             delAACCCGGG    c.-3066_c.-3059    54422006-54421999        ins \> del   0.039    0.059                   0.65 (0.33-1.27)    0.202
             rs2855530      c.-2977            54421917                 C \> G       0.418    0.369                   1.23 (0.93-1.62)    0.146
  BMP4.2     rs113141288    c.-2932            54421872                 G \> T       0.041    0.052                   0.78 (0.41-1.50)    0.455
             rs76953585     c.-2679            54421619                 C \> T       0.044    0.054                   0.79 (0.42-1.50)    0.484
             rs113562279    c.-2608            54421548                 G \> T       0.038    0.052                   0.70 (0.35-1.37)    0.295

^a^Chromosome position according to genome assembly GRCh37.

^b^MAF: Minor allele frequency.

The polymorphic variants detected in BMP4.1 and BMP4.2 in NSCLP cases and controls in the total sample are shown in Table [2](#T2){ref-type="table"}. Two SNPs were found in BMP4.1: rs2855527 and rs77671695, and four SNPs in BMP4.2: rs2855530, rs113141288, rs76953585 and rs113562279. No significant differences in the allele frequencies were observed between cases and controls (Table [1](#T1){ref-type="table"}). When the sample was subdivided by gender, only the G allele of rs2855530 within BMP4.2 showed a greater frequency in male cases than in controls (OR = 1.52; 95% C.I. = 1.07-2.15; p = 0.019). This difference was not observed in female participants (OR = 0.78; 95% C.I. = 0.48-1.25; p = 0.297) (Table [2](#T2){ref-type="table"}). (The just mentioned ORs and p-values had exactly the same values when were calculated by *UNPHASED*and *PLINK*).

###### 

Allelic association between BMP4.1 and BMP4.2 polymorphisms and NSCLP subdivided by gender.

  Promoter   Polymorphism   Males MAF^a^   Odds Ratio (95% C.I.)   p-value              Females MAF^\#^   Odds Ratio (95% C.I.)   p-value                           
  ---------- -------------- -------------- ----------------------- -------------------- ----------------- ----------------------- -------------- ------------------ -------
                            **Cases**      **Controls**                                                   **Cases**               **Controls**                      
                                                                                                                                                                    
  BMP4.1     rs2855527      0.0047         0.0027                  1.74 (0.11-27.95)    0.692             0.000                   0.0033         \-\--              \-\--
             rs77671695     0.042          0.057                   0.73 (0.33-1.63)     0.444             0.035                   0.052          0.65 (0.21-2.00)   0.454
                                                                                                                                                                    
             delAACCCGGG    0.029          0.060                   0.47 (0.19-1.17)     0.099             0.059                   0.058          1.01 (0.39-2.64)   0.982
             rs2855530      *0.456*        *0.356*                 *1.52 (1.07-2.15)*   *0.019*           0.327                   0.384          0.78 (0.48-1.25)   0.297
  BMP4.2     rs113141288    0.043          0.051                   0.84 (0.37-1.92)     0.685             0.036                   0.054          0.66 (0.21-2.00)   0.456
             rs76953585     0.042          0.058                   0.71 (0.32-1.59)     0.405             0.045                   0.050          0.91 (0.32-2.57)   0.860
             rs113562279    0.037          0.058                   0.63 (0.27-1.45)     0.273             0.037                   0.046          0.78 (0.25-2.41)   0.295

^a^MAF: Minor allele frequency.

Genotypes for BMP4.1 and BMP4.2 SNPs showed no significant deviations from Hardy-Weinberg expectations both in cases and controls (data not shown). The results of the genotype association analysis for BMP4.1 SNPs showed that only rs2855530 in BMP4.2 showed a positive association of C/G genotype (OR = 1.75; 95% C.I. = 1.14-2.69; p = 0.012) while an inverse relation was observed for the C/C genotype (OR = 0.79; 95% C.I. = 0.43-1.47; p = 0.020) (Table [3](#T3){ref-type="table"}). *PLINK*software does not show an individual p-value for each genotype case-control comparison. However, the genotype association displayed a significant difference when G/G+C/G frequencies were compared with C/C frequencies. Thus, G/G+C/G were more frequent in cases than controls while C/C was more frequent in controls than cases (p = 0.032) (data not shown).

###### 

Genotype association between BMP4.1 and BMP4.2 polymorphisms and NSCLP.

  Promoter   Polymorphism   Genotypes   Frequency   Odds Ratio (95% C.I.)   p-value              
  ---------- -------------- ----------- ----------- ----------------------- -------------------- ---------
             rs2855527      T/T         0.9938      0.9941                  Ref.                 
  BMP4.1                    T/G         0.0062      0.0059                  1.04 (0.09-11.6)     0.972
                                                                                                 
             rs77671695     T/T         0.92        0.89                    Ref.                 
                            T/G         0.08        0.11                    0.71 (0.36-1.37)     0.308
                                                                                                 
             delAACCCGGG    Ins/Ins     0.92        0.88                    Ref.                 
                            Ins/Del     0.08        0.12                    0.63 (0.32-1.25)     0.189
                                                                                                 
                            G/G         0.14        0.15                    Ref.                 
             rs2855530      C/G         0.56        0.44                    *1.75 (1.14-2.69)*   *0.012*
                            C/C         0.30        0.41                    *0.79 (0.43-1.47)*   *0.020*
                                                                                                 
  BMP4.2     rs113141288    G/G         0.92        0.90                    Ref.                 
                            G/T         0.08        0.10                    0.77 (0.39-1.50)     0.443
                                                                                                 
             rs76953585     C/C         0.92        0.89                    Ref.                 
                            C/T         0.08        0.11                    0.78 (0.41-1.51)     0.472
                                                                                                 
             rs113562279    G/G         0.92        0.89                    Ref.                 
                            G/T         0.08        0.11                    0.69 (0.34-1.36)     0.282

In male participants, the C/G genotype of rs2855530 showed an OR = 2.34 (95% C.I. = 1.33-4.09; p = 0.011) and the C/C genotype presented an OR = 0.51 (95% C.I. = 0.23-1.09; p = 0.003) while the same comparisons were non-significant for female participants (Table [4](#T4){ref-type="table"}). Analysis performed by *PLINK*once again corroborate these results. Thus, the G/G+C/G versus C/C comparison was more significant between male cases and male controls than the total sample (p = 0.003).

###### 

Genotype association between BMP4.1 and BMP4.2 polymorphisms and NSCLP subdivided by gender

                                                    Males           Females                                                                                                                        
  -------------- ------------------ --------------- --------------- --------------------------- -------------------- --------------- --------------------------- -------------- ------------------ -------
  **Promoter**   **Polymorphism**   **Genotypes**   **Frequency**   **Odds Ratio (95% C.I.)**   **p-value**          **Frequency**   **Odds Ratio (95% C.I.)**   **p-value**                       
                                                    **Cases**       **Controls**                                                     **Cases**                   **Controls**                      
                                                                                                                                                                                                   
                 rs2855527          T/T             0.9906          0.9946                      Ref.                                 1.0000                      0.9934         Ref.               
  BMP4.1                            T/G             0.0094          0.0054                      1.74 (0.10-28.16)    0.692           0.0000                      0.0065                            
                                                                                                                                                                                                   
                 rs77671695         T/T             0.92            0.89                        Ref.                                 0.93                        0.89           Ref.               
                                                                                                                                                                                                   
                                    T/G             0.08            0.11                        0.72 (0.32-1.63)     0.431           0.07                        0.11           0.64 (0.21-2.01)   0.443
                                                                                                                                                                                                   
                 delAACCCGGG        Ins/Ins         0.94            0.88                        Ref.                                 0.88                        0.88           Ref.               
                                    Ins/Del         0.06            0.12                        0.45 (0.17-1.15)     0.090           0.12                        0.12           1.01 (0.38-2.73)   0.982
                                                                                                                                                                                                   
                                    G/G             0.17            0.14                        Ref.                                 0.08                        0.16           Ref.               
                 rs2855530          C/G             0.58            0.43                        *2.34 (1.33-4.09)*   *0.011*         0.50                        0.45           2.23 (0.71-7.08)   0.583
  BMP4.2                            C/C             0.25            0.43                        *0.51 (0.23-1.09)*   *0.003*         0.42                        0.39           2.21 (0.69-7.15)   0.655
                                                                                                                                                                                                   
                 rs113141288        G/G             0.91            0.90                        Ref.                                 0.93                        0.89           Ref.               
                                    G/T             0.09            0.10                        0.83 (0.36-1.93)     0.677           0.07                        0.11           0.64 (0.20-2.01)   0.444
                                                                                                                                                                                                   
                 rs76953585         C/C             0.92            0.88                        Ref.                                 0.91                        0.90           Ref.               
                                    C/T             0.08            0.12                        0.69 (0.31-1.59)     0.392           0.09                        0.10           0.91 (0.31-2.62)   0.857
                                                                                                                                                                                                   
                 rs113562279        G/G             0.93            0.88                        Ref.                                 0.93                        0.91           Ref.               
                                    G/T             0.07            0.12                        0.62 (0.26-1.44)     0.261           0.07                        0.09           0.77 (0.24-2.44)   0.653

According to *Tfsitescan*and *MatInspector*softwares, the change observed in c.-5514 position generates a new site for GATA-1. The variant c.-5365C \> T produces a sequence that can be potentially recognized by a RXR heterodimer transcription factor. The change T for C in c.-5049 introduced a previously inexistent site for TCF-1α. Finally, in the case of BMP4.2, this same bioinformatic analyses showed that rs2855530 G allele generated a Sp1 binding motif which is not detected when the C allele is present. Therefore, the bioinformatic analyses of the genetic variants c.-5514G \> A, c.-5365C \> T and c.-5049C \> T within BMP4.1 and the SNP rs2855530 within BMP4.2 showed that they are capable of creating mammalian transcription factor binding motifs.

Discussion
==========

Regulatory variants are important in the understanding of the phenotypic diversity and the role they play in the susceptibility of complex diseases. However, it is noteworthy that these regulatory variants have not received the same scientific interest in comparison to coding variants \[[@B30]\]. According to the *Human Gene Mutation Database*<http://www.hgmd.cf.ac.uk/ac/index.php> approximately 1.6% of single base-pair substitutions described are regulatory mutations. Furthermore, there is abundant evidence indicating that regulatory SNPs (rSNPs) have an impact in the phenotypic diversity and can also affect disease susceptibility interacting with other variants located in their vicinity \[[@B31]\]. All these changes can potentially disrupt the DNA motifs recognized by transcription factors and consequently alter the normal processes of gene activation and/or transcriptional regulation \[[@B32]\]. In this context and taking into account the absent of NSCLP causal mutations in *BMP4*coding regions plus the evidence of haplotype association reported by Suazo et al \[[@B20]\], the present report was focused in detecting NSCLP risk variants within both *BMP4*promoters. In accordance with our previous report we found NSCLP risk variants within *BMP4*promoters. Due to their frequencies it was impossible to establish if these novel variants are in linkage disequilibrium with those SNPs associated with NSCLP described by Suazo et al.

For BMP4.1 three novel substitutions were detected in cases (c.-5514G \> A, c.-5365C \> T and c.-5049C \> T) which can be considered as potential susceptibility variants due to their absence in controls. Moreover, c.-5365T and c.-5049T were found in the same NSCLP case and they were inherited from his healthy mother. Therefore, although that this haplotype can be considered a risk factor it cannot produce the expression of NSCLP by itself and it would need other genetic variants and/or environmental factors absent in this case\'s mother. In tune with our findings, several mutations have been identified in NSCLP candidate genes mainly in sporadic cases \[[@B11]\]. For this reason these variants can be considered as private mutations from private families. The novel variants described in our study present the same characteristic shared by private mutations from private families.

In BMP4.2 we did not detect novel allelic variants. Regarding polymorphisms, SNP rs2855530 showed an association with NSCLP which presented a sexual dimorphism. Combining the results of association analyses using *UNPHASED*and *PLINK*softwares we can conclude that rs2855530 G allele and the G/G+C/G genotype (dominant model) should be considered risk factors but restricted to males due to their higher frequency in male cases than in male controls. On the other hand, the C/C genotype seems to represent a protective factor for male individuals given that its frequency is higher in male controls. Our group has previously reported a sexual or gender dimorphism for NSCLP where an STR allele of *MSX1*gene showed significant differences between male cases and male controls \[[@B33]\]. Using animal models, sex-biased gene expression has been reported for gonadal and extragonadal tissues during embryogenesis where the major determinants of these differences are sex hormones \[[@B34],[@B35]\]. The human adult face displays a sexual dimorphism which seems to be established in the first years of life but could depend on factors expressed in the prenatal life \[[@B36]\]. These evidences and our findings in the present study are closely linked with epidemiological findings showing a higher frequency of NSCLP in males than females.

The bioinformatic analysis of the risk variants predicts that they could create new transcription factor binding motifs which could be involved in NSCLP. The c.-5514A allele of BMP4.1 could introduce a new site for the hematopoietic transcription factor GATA-1 \[[@B37]\]. A different site for this factor has been reported within the human BMP4.1 promoter and it has been demonstrated that it produces a negative effect on *BMP4*expression \[[@B22]\]. The c.-5365T allele also generates a consensus sequence for RXR transcription factor which is related with gene expression regulated by retinoic acid (RA). This situation may explain why teratogenic doses of RA induce cleft palate in *Rxr-α*knockout mice in a lower frequency than in wild-type animals \[[@B38]\]. The BMP4.1 c.-5049T allele introduces a novel site for TCF-1α, a canonical Wnt pathway effector which is expressed in the processes that originate the mice midface \[[@B39],[@B40]\]. For BMP4.2, the bioinformatic analysis predicted that the rs2855530G allele generates a novel binding site for Sp1, an ubiquitous transcription factor. Sp1 can modulate the gene expression in cellular processes like differentiation, growth and apoptosis, among others \[[@B41]\]. Nevertheless, there is no information about Sp1 inactivation or overexpression related to craniofacial anomalies.

To our knowledge, the present study constitutes the first report detecting novel risk regulatory variants for a NSCLP candidate gene. In this context, three previous studies have associated rSNPs with this birth defect: this is the case of rs642961 located in an *IRF6*enhancer, rs28999109 within the *PDGF-C*promoter, and rs16260 located in the *CDH1*promoter \[[@B42]-[@B44]\]. The bioinformatic analysis for *IRF6*and *PDGF-C*variants showed that the risk alleles disrupt potential transcription factor motifs. Nevertheless, reporter gene assays demonstrated that significant alterations in gene expression were detected only for the *PDGF-C*promoter variant \[[@B43]\]. Following the tendency set by these latter articles, functional studies are necessary to confirm our findings.

Conclusions
===========

In summary, we have detected three novel NSCLP potential causal variants in *BMP4*promoters which could contribute to approximately 1.2% of this birth defect, as well as a risk SNP allele with a clear sex dependent association (rs2855530). These results are in concordance with our previous report showing the absence of potential causal mutations in the coding sequence of *BMP4*. The bioinformatic analyses have predicted that all these variants can potentially generate novel transcription factor recognition sites. In future reports will be necessary to confirm the *invivo*capability of these variants to alter *BMP4*expression using functional and developmental approaches.
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